According to its own reports, Novartis put "BioFuture" into operation, which represents the world's most advanced facility for manufacturing therapeutic proteins by means of continuing and automated process technologies. Compared to conventional plants, the set-up is much more flexible, enabling the highly efficient production of biopharmaceutical substances and the quick conversion to new products.
The new production facility will create 80 new jobs when operating at full capacity. According to the company itself, the investment volume of € 160 million for the new plant represents the biggest single investment within the Group at the present time.
Continue reading and find out more about the life sciences sector in Austria!